Publications by authors named "Hamit Bal"

Claim this Profile
R
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.
Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel, Caner Acar, Imge Akın, Hamit Bal

Discov Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group.
Salih Tunbekici, Gokhan Sahin, Sercan Ön, Ahmet Oruc, Melek Karakurt Eryılmaz, Hamit Bal

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.
Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel, Caner Acar, Imge Akın, Hamit Bal

Int J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer.
Oğuzcan Kınıkoğlu, Yunus Emre Altıntaş, Anıl Yıldız, Goncagül Akdağ, Hamit Bal

Oncologist· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Goncagul Akdag, Sedat Yildirim, Akif Dogan, Zeynep Yuksel Yasar, Hamit Bal

Chemotherapy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
Oğuzcan Kınıkoğlu, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Hamit Bal

Medicina (Kaunas)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Zeynep Yüksel Yasar, Hamit Bal

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ticagrelor-associated thrombotic thrombocytopenic purpura.
Ali Doğan, Behzat Özdemir, Hamit Bal, Emrah Özdemir, Nuri Kurtoğlu

Anatol J Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis